E. Griese

发表

Diclofenac does not interact with codeine metabolism in vivo: A study in healthy volunteers

U. Hofmann, G. Mikus, T. Mürdter, 2002, BMC clinical pharmacology.

Shed human enterocytes as a tool for the study of expression and function of intestinal drug‐metabolizing enzymes and transporters

H. Glaeser, M. Fromm, M. Eichelbaum, 2002, Clinical pharmacology and therapeutics.

Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer.

H. Kroemer, P. Fritz, K. Kivistö, 1997, Pharmacogenetics.

Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.

M. Eichelbaum, G. Mikus, D. Ofori-Adjei, 1999, Pharmacogenetics.

Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia.

M. Eichelbaum, R. Minchin, N. Kitteringham, 2001, Pharmacogenetics.

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.

M. Fromm, H. Kroemer, K. Kivistö, 2003, British journal of clinical pharmacology.

Beta-thalassemia gene analysis in a Turkish family reveals a 7 BP deletion in the coding region.

A. Eigel, J. Horst, E. Griese, 1989, Blood.

Telomeres in Neonates: New Insights in Fetal Hematopoiesis

U. Klotz, M. Schwab, P. Fritz, 2001, Pediatric Research.

Hemoglobin M Iwate is caused by a C→T transition in codon 87 of the human α1-globin gene

G. Assum, E. Kohne, A. Eigel, 1987, Human Genetics.

Heterogeneity of the α-globin gene defects in German α-thalassemia affected families

E. Kohne, J. Horst, E. Griese, 2004, Human Genetics.

α-Globin gene deletion causes α-thalassemia syndromes in two German families

E. Kohne, J. Horst, E. Griese, 2004, Human Genetics.

Detection of a restriction site polymorphism within the human α-globin gene complex

G. Assum, J. Horst, E. Griese, 2004, Human Genetics.

The efficacy of simvastatin is not influenced by CYP2D6 polymorphism.

M. Eichelbaum, J. Geisel, K. Kivistö, 2002, Clinical pharmacology and therapeutics.

Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2'-O-methyl-RNA.

U. Klotz, C. Lehr, B. Loretz, 2011, International journal of pharmaceutics.

Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.

C. Meisner, M. Eichelbaum, M. Schwab, 2002, Pharmacogenetics.

Relevance of deficient CYP2D6 in opiate dependence.

U. Klotz, K. Mörike, G. Mikus, 1998, Pharmacogenetics.

Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans

U. Hofmann, M. Fromm, G. Mikus, 1995, Clinical pharmacology and therapeutics.

Fatal MDMA intoxication

M. Schwab, E. Griese, R. Brauer, 1999, The Lancet.

Inactivation of human alpha-globin gene expression by a de novo deletion located upstream of the alpha-globin gene cluster.

D. Higgs, S. Liebhaber, J. Horst, 1990, Proceedings of the National Academy of Sciences of the United States of America.

A novel intronic mutation, 2988G>A, with high predictivity for impaired dunction of cytochrome P450 2D6 in white subjects

M. Eichelbaum, M. Schwab, U. Zanger, 2004, Clinical pharmacology and therapeutics.

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.

M Schwab, M. Eichelbaum, M. Schwab, 2000, Pharmacogenetics.

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.

M. Eichelbaum, A. Gaedigk, K. Mörike, 1998, Pharmacogenetics.

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.

D. Schrenk, M. Eichelbaum, K. Bock, 1994, Pharmacogenetics.

Telomere length in different tissues of elderly patients

U. Klotz, M. Schwab, P. Fritz, 2000, Mechanisms of Ageing and Development.

Competitive nested polymerase chain reaction for quantification of humanMDR1 gene expression

K. Schumacher, E. Griese, F. Grünebach, 2005, Journal of Cancer Research and Clinical Oncology.

Nanoparticle mediated delivery of 2'-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells.

U. Klotz, C. Lehr, U. Schaefer, 2010, Lung cancer.

Differential expression and function of CYP2C isoforms in human intestine and liver.

M. Fromm, M. Eichelbaum, K. Kivistö, 2003, Pharmacogenetics.

[Experiences with prenatal diagnosis of sickle cell anemia and thalassemias in the first trimester of pregnancy: various aspects for the obstetrician].

W. Holzgreve, P. Miny, J. Horst, 1987, Geburtshilfe und Frauenheilkunde.

Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction.

M. Eichelbaum, H. Kroemer, U. Zanger, 1996, Pharmacogenetics.

Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon.

M. Eichelbaum, B. Evert, E. Griese, 1994, Pharmacogenetics.

Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine.

M. Eichelbaum, Lucia F. Jorge-Nebert, E. Griese, 2002, Pharmacogenetics.

Allele‐specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples

A. Rosenwald, G. Ott, E. Griese, 2015, British journal of haematology.

Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours

P. Beaune, H. Kroemer, J. Hakkola, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients

W. Maier, K. Mörike, E. Griese, 2001, European Journal of Clinical Pharmacology.

Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations.

M. Eichelbaum, E. Griese, T. D. Arias, 1999, Pharmacogenetics.

Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction.

M. Eichelbaum, E. Griese, F. Läpple, 1999, Pharmacogenetics.

Propafenone in a usual dose produces severe side‐effects: the impact of genetically determined metabolic status on drug therapy

T. Mettang, U. Kuhlmann, K. Mörike, 1995, Journal of internal medicine.

Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing.

U. Hofmann, G. Mikus, S. Ammon, 1999, British journal of clinical pharmacology.

A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine

M. Eichelbaum, B. Evert, E. Griese, 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

A missense mutation in exon 6 of the CYP2D6 gene to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine leading

B. Evert, E. Griese, Michel Eicheibaum, 1994 .

Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.

G. Barth, M. Köhnke, E. Griese, 2002, Pharmacopsychiatry.

Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Colombia: high frequencies of point mutation 857A, as found in allele S3/M3.

M. Eichelbaum, E. Griese, T. D. Arias, 1993, Pharmacogenetics.

Diclofenac does not interact with codeine metabolism in vivo: A study in healthy volunteers

U. Hofmann, G. Mikus, T. Mürdter, 2002, BMC clinical pharmacology.